Literature DB >> 10692673

Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.

H Kurotaki1, Y Tsushima, K Nagai, S Yagihashi.   

Abstract

Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS). To explore the role of apoptosis in hematological disorders, we examined the frequency of apoptotic cells by the in situ end labeling method in bone marrow specimens from 37 patients with MDS [refractory anemia (RA) 10 cases, RA with excess of blasts (RAEB) 27 cases including 12 cases with leukemic transformation], 12 patients with MDS-derived acute myelogenous leukemia (AML) and 13 patients with de novo AML. In addition, we investigated the relationship of apoptosis to the immunohistochemical expression of bcl-2 and p53 in these cases, and the association of apoptosis, bcl-2, and p53 with the leukemic evolution of MDS by examining sequential bone marrow samples of the same patient from the time of initial diagnosis to the time of overt leukemia. The percentage frequency of apoptotic cells was significantly greater in MDS (RA: 9.46 +/- 2.99%, m +/- SD; RAEB: 5. 60 +/- 3.09) as compared with those in MDS-derived AML (0.62 +/- 0. 37), de novo AML (0.28 +/- 0.11) and controls (1.00 +/- 0.59). On the other hand, the cases of RAEB with leukemic transformation exhibited a lower frequency of apoptotic cells and a higher frequency of bcl-2- and p53-positive cells than those without transformation. When the RAEB cases transformed to AML, the frequency of apoptotic cells was significantly reduced (2.96 +/- 1. 54 --> 0.62 +/- 0.37), while the frequencies of bcl-2-positive cells and p53-positive cells were greater (10.88 +/- 3.66 --> 30.54 +/- 7. 14, and 20.21 +/- 6.21 --> 32.34 +/- 14.71, respectively). In contrast to MDS-derived AML, over a half of de novo AML cases showed few p53-positive cells. These findings corroborate the earlier notion that apoptosis may play a substantial role in dysplastic and ineffective hematopoiesis in MDS. It is also suggested that the suppression of apoptosis associated with enhanced bcl-2 expression and p53 accumulation increases the probability of developing leukemia in MDS, and that oncogenetic development might be different between MDS-derived AML and de novo AML. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10692673     DOI: 10.1159/000040984

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  17 in total

1.  F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia.

Authors:  Jong Weon Choi; Masahiko Fujino; Masafumi Ito
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

2.  p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Authors:  Leonie Saft; Mohsen Karimi; Mehran Ghaderi; András Matolcsy; Ghulam J Mufti; Austin Kulasekararaj; Gudrun Göhring; Aristoteles Giagounidis; Dominik Selleslag; Petra Muus; Guillermo Sanz; Moshe Mittelman; David Bowen; Anna Porwit; Tommy Fu; Jay Backstrom; Pierre Fenaux; Kyle J MacBeth; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

3.  Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.

Authors:  Yue Zhang; Xiaomei Yan; Goro Sashida; Xinghui Zhao; Yalan Rao; Susumu Goyama; Susan P Whitman; Nicholas Zorko; Kelsie Bernot; Rajeana M Conway; David Witte; Qian-Fei Wang; Daniel G Tenen; Zhijian Xiao; Guido Marcucci; James C Mulloy; H Leighton Grimes; Michael A Caligiuri; Gang Huang
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

4.  Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine.

Authors:  Alena Moudra; Sona Hubackova; Veronika Machalova; Marketa Vancurova; Jiri Bartek; Milan Reinis; Zdenek Hodny; Anna Jonasova
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

Review 5.  The role of apoptosis in the pathogenesis of the myelodysplastic syndromes.

Authors:  Jane E Parker; Ghulam J Mufti
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

6.  Apoptotic rate in patients with myelodisplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines.

Authors:  Elena Moldoveanu; Andreea Moicean; Cristina Vidulescu; Daciana Marta; Adriana Colita
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

7.  Bone marrow cell cycle markers in inherited bone marrow failure syndromes.

Authors:  Mohamad M Al-Rahawan; Blanche P Alter; Barbara J Bryant; M Tarek Elghetany
Journal:  Leuk Res       Date:  2008-07-07       Impact factor: 3.156

8.  Identification of DJ-1/PARK-7 as a determinant of stroma-dependent and TNF-alpha-induced apoptosis in MDS using mass spectrometry and phosphopeptide analysis.

Authors:  A Mario Marcondes; Xiang Li; Ted A Gooley; Brian Milless; H Joachim Deeg
Journal:  Blood       Date:  2010-01-08       Impact factor: 22.113

9.  The role of apoptosis and current therapeutic challenges in myelodysplastic syndromes.

Authors:  M Diamantidis; S Dimoudis; Ph Klonizakis; K Badekas; K Koutourli; S Haralambidou-Vranitsa; E Ioannidou-Papagiannaki
Journal:  Hippokratia       Date:  2007-10       Impact factor: 0.471

Review 10.  Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.

Authors:  Eric Goethe; Bing Z Carter; Ganesh Rao; Naveen Pemmaraju
Journal:  J Neurooncol       Date:  2017-12-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.